|
Fig. 8
Neratinib does not alter the numbers or distribution of circulating leukocytes in chronic mouse models of lung disease. Leukocytes in mouse whole-blood samples were analyzed using an automated hematology blood analyzer, which counts total leukocytes as well as differentiates between lymphocytes, neutrophils, and monocytes; the percentages of each leukocyte subset are also analyzed. No differences in the number of leukocytes, or their subsets, were identified between the vehicle- and neratinib-treated groups in the induction dosing (A) or therapeutic dosing (B) model, and similarly, no differences in the percentages of lymphocytes, neutrophils, and monocytes were found between treatment groups in the induction (C) or therapeutic (D) dosing model. Each data point represents data from one mouse; bars show mean ± standard deviation. Unpaired t-tests were used to compare treatment groups within each cell type; p-values were indicated where appropriate.